Mitobridge Inc. Overview
Pro stress-test →Mitobridge Inc. is a biotechnology company that discovers and develops small molecule therapeutics targeting mitochondrial dysfunction across rare and common diseases. Founded in 2013, the company was acquired by Japan-based Astellas Pharma in January 2018 for up to $450 million, becoming a wholly-owned subsidiary focused on drug discovery and development.
Strategic Profile
Pro stress-test →Mitobridge employs a two-stage market strategy: establishing proof of concept in rare genetic and metabolic disorders before expanding into larger disease categories with unmet medical needs. The company leverages deep expertise in mitochondrial biology and metabolism, leveraging its innovative screening platform to advance novel therapeutics from preclinical development into clinical stages.
Competitive Landscape
Pro stress-test →Mitobridge competes in the mitochondrial dysfunction therapeutics space alongside biotech companies focused on metabolic and genetic disorders. Key competitors include Mighty Therapeutics, ALKemist Bio, Phaxiam, Allorion Therapeutics, and Cognition Therapeutics, each pursuing different mechanisms to address rare disease and neurodegeneration markets.
Industry Context
Mitobridge Inc. operates in Mitochondrial dysfunction therapeutics.
Key facts
Founded: 2013 · Headquarters: Cambridge, MA, US · Employees: 26 · Revenue: N/A (subsidiary of Astellas Pharma) · Market cap: N/A